500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI

Fudan University130 enrolled

Overview

500mg Fulvestrant versus Everolimus plus Exemestane in MBC patients refractory to previous AI

Fulvestrant versus Everolimus plus Exemestane for patients with Metastatic Breast Cancer resistant to Aromatase Inhibitors: the clinical experience from real -world

Study Type

OBSERVATIONAL

Enrollment

130

Conditions

Breast Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients diagnosed with ER/PR+，HER2- Metastatic Breast Cancer 2. Patients who were refractory to previous Aromatase Inhibitors 3. Patients treated with Fulvestrant or Everolimus plus Exemestane in any line in metastatic setting in Fudan University Shanghai Cancer Center，starting from 2013.06.01-2016.06.01 4. Available medical history Exclusion Criteria: 1.Incomplete medical history

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

PFS

Progression free survival

Time frame: 6 weeks

Secondary Outcomes

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.